Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | PPP1R15A | O75807 | 1/20 | 0.59 |
| ▸ | MELK | Q14680 | 1/20 | 0.59 |
| ▸ | PPP1R15B | Q5SWA1 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30275282 | 1.00 | L3MBTL1 (0.59) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL379833 | 0.82 | GRIN1 (0.57) | NPSR1SMN1; SMN2ALDH1A1LMNAKMT2A | |
| SCHEMBL379834 | 0.82 | GRIN1 (0.57) | NPSR1SMN1; SMN2ALDH1A1LMNAKMT2A | |
| SCHEMBL805947 | 0.79 | PPP1R15A (0.40) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL3697881 | 0.79 | GAA (0.44) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL2161103 | 0.78 | L3MBTL1 (0.59) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL534017 | 0.78 | L3MBTL1 (0.59) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL534016 | 0.78 | L3MBTL1 (0.59) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL32680261 | 0.78 | L3MBTL1 (0.59) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 | |
| SCHEMBL1612865 | 0.78 | L3MBTL1 (0.55) | L3MBTL1PPP1R15AMELKPPP1R15BNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-05 | — | — | US | claimed |
| WO-2002102301-A2 | SUBSTITUTED INDOLE-2-CARBOXYLIC ACID BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-12-27 | — | — | WO | claimed |
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-09-12 | — | — | US | claimed |
| US-6747052-B2 | ANTICANCER AGENTS | CYTOVIA, INC. | 2004-06-08 | — | — | US | disclosed |
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2002102301-A2 | SUBSTITUTED INDOLE-2-CARBOXYLIC ACID BENZYLIDENE-HYDRAZIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128292-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | BAD, API5, CASP2 | L3MBTL1 1507/4885PPP1R15A 1964/4885MELK 2947/4885 |
| US-20030105140-A1 | Substituted indole-2-carboxylic acid benzylidene-hydrazides and analogs as activators of caspases and inducers of apoptosis and the use thereof | BAD, API5, CASP2 | L3MBTL1 1507/4885PPP1R15A 1964/4885MELK 2947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.